GlassScriptPhysician profile
Ian Yang
NPI 1225146939
$1,176.37
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $188 · 2021: $409.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $692.92 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $191.28 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $69.62 | 2019 | |
| Arbor Pharmaceuticals, INC. | $43.82 | 2019-2021 | |
| Redhill Biopharma INC. | $26.60 | 2021 | |
| Daiichi Sankyo INC. | $22.71 | 2019 | |
| Almatica Pharma LLC | $20.87 | 2021 | |
| Pfizer INC. | $12.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.